Quest Diagnostics (DGX) Tops Q2 EPS by 30c; updates guidance

Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $3.12, $0.30 better than the analyst estimate of $2.82. Revenue for the quarter came in at $3.04 billion versus the consensus estimate of $2.97 billion.

GUIDANCE:

Quest Diagnostics sees FY2026 EPS of $11.05-$11.25, versus the consensus of $10.77. Quest Diagnostics sees FY2026 revenue of $11.95-12.05 billion, versus the consensus of $11.853 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• EQT And KKKR Said Among Firms Considering Bids For Qiagen - Bloomberg
• Truist Securities on JFrog (FROG): 'Multiple Paths to Sustained Growth Beyond FY26'
• Pinduoduo (PDD) Tops Q2 EPS by 98c